华海药业(600521.SH)获得盐酸纳洛酮注射液药品注册证书

Core Viewpoint - Huahai Pharmaceutical (600521.SH) has received the drug registration certificate for Naloxone Hydrochloride Injection from the National Medical Products Administration, indicating a significant regulatory approval for the company [1] Group 1: Product Approval - The approval allows the company to market Naloxone Hydrochloride Injection, which is indicated for multiple uses including reversing respiratory depression caused by opioid drugs [1] - The drug is also indicated for the treatment of opioid overdose, acute ethanol poisoning, and for diagnostic purposes in cases of acute opioid overdose [1]